

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned 09/351,617
	Filing Date	July 12, 1999
	First Named Inventor	Mehta
	Group Art Unit	Not Yet Assigned 1627
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	15966-518

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,488,614	11/21/95	Fields			
	A2	5,469,285	11/24/95	Gut			
	A3	5,871,753	2/16/99	Crabtree			
	A4	5,928,868	7/27/99	Liu			

cited in PTO 1449 filed on 12/9/99

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 94/230925	Fowlkes		
	B2	WO 95/30012	Broach		
	B3	WO 95/02684	Crabtree		
	B4	WO 96/13613	Schreibler		
	B5	WO 96/08097	Holt		

cited in PTO 1449 filed on 12/9/99

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Abramson <i>et al.</i> , J MED CHEM, 34 (6), 1798-804 (1991). <i>cited in PTO 1449</i>
	C2	Ausubel, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY CHAPTER 9, 1994.
	C3	Boopathy <i>et al.</i> , BIOCHEM J., 239 (2), 371-7 (1986). <i>cited in PTO 1449</i>
	C4	Born <i>et al.</i> , J. BIOL CHEM, 270 (43), 25651-5 (1995).
	C5	Durfee <i>et al.</i> , GENES AND DEVELOPMENT, 7, 555-569 (1993).
	C6	Edwards <i>et al.</i> , J MED CHEM, 38 (1), 76-85 (1995).
	C7	Goodman <i>et al.</i> , THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, (1996).
	C8	Griffin <i>et al.</i> , SCIENCE, 281 (5374), 269-72 (1998). <i>cited in PTO 1449</i>
	C9	Hanzlik <i>et al.</i> , BIOCHIM BIOPHYS ACTA, 1035(1), 62-70 (1990).
	C10	Li <i>et al.</i> , J STEROID BIOCHEM, 36 (6), 533-9 (1990).
	C11	Licitra <i>et al.</i> , PROC NATL ACAD SCI USA, 93 (23), 12817-21 (1996).
	C12	March, ADVANCED ORGANIC CHEMISTRY, (1972).
	C13	Mendelsohn <i>et al.</i> , CURR OPIN BIOTECHNOL, 5 (5), 482-486 (1994). <i>cited in PTO 1449</i>
	C14	Michels <i>et al.</i> , TRENDS, 16 (5), 210-5 (1998).

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
<input checked="" type="checkbox"/>	C15	Mueller et al., PROC NATL ACAD SCI USA, 92 (18), 8383-7 (1995).
<input checked="" type="checkbox"/>	C16	O'Brien et al., J NEURAL TRASM SUPPL, 41, 295-305 (1994).
<input checked="" type="checkbox"/>	C17	Pruschy, CHEM BIOL, 1, 163-172 (1994).
<input checked="" type="checkbox"/>	C18	Roth et al., J BIOL CHEM, 253 (11), 3782-4 (1978).
<input checked="" type="checkbox"/>	C19	Salto et al., 269 (14), 10691-8 (1994).
<input checked="" type="checkbox"/>	C20	Schenkein et al., J BIOL CHEM, 255 (1), 45-8, (1980).
<input checked="" type="checkbox"/>	C21	Silverman, METHODS ENZYMOL, 249, 240-83 (1995).
<input checked="" type="checkbox"/>	C22	Singh et al., J MED CHEM, 40 (7), 1130-5 (1997).
<input checked="" type="checkbox"/>	C23	Snider et al., J STEROID BIOCHEM, 22(3), 325-30 (1985).
<input checked="" type="checkbox"/>	C24	Tous et al., J MED CHEM, 33(6), 1620-34 (1990).
<input checked="" type="checkbox"/>	C25	Yang et al., NUCLEIC ACIDS RES, 23 (7), 1152-6 (1995).
<input checked="" type="checkbox"/>	C26	Zaugg et al., J BIOL CHEM, 255 (7), 2816-21 (1980).
<input checked="" type="checkbox"/>	C27	Zhang et al., J MED CHEM, 40(1), 4-8 (1997).

cited in PTO 1449, filed on 8/19/99

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>P. Ponnaluri</i>	Date Considered	10/18/00
--------------------	---------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.


Include copy of this form with next communication to applicant.

Express Mail Label No.: EE327623634US

Date of Deposit: 12/09/99

PATENT APPLICATION
Attorney Docket No. 15966-518 (Cura-18)

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/351,617
	Filing Date	07/12/99
	First Named Inventor	Mehta, et al.
	Group Art Unit	4643 1627
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	15966-518

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
pp ↓	A1	5,468,614	12/21/95	Fields, et al.	—	—	
	A2	5,469,285	12/21/95	Gut	—	—	
	A3	5,871,753	02/16/99	Crabtree, et al.	—	—	
	A4	5,928,868	07/27/99	Liu and Licitra	—	—	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
pp ↓	B1	WFO 94/23025	Fowkes, et al.	—	✓	
	B2	WFO 95/02684	Crabtree, et al.	—	✓	
	B3	WFO 95/30012	Broach, et al.	—	✓	
	B4	WFO 96/06097	Holt, et al.	—	✓	
	B5	WFO 96/13613	Schreiber, et al.	—	✓	
	B6	WFO 97/41255	Liu et al.	—	✓	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
pp ↓	C1	Abramson et al., "Structure/Activity and Molecular Modeling Studies of the Lophotoxin Family of Irreversible Nicotinic Receptor Antagonists." J. Med. Chem. 34: 1798-1804 (1991).
	C2	Boopathy et al., "Purification and characterization of sheep platelet cyclo-oxygenase." Biochem. J. 239: 371-377 (1986).
	C3	Born et al., "4-(Fluoromethyl)phenyl Phosphate Acts as a Mechanism-based Inhibitor of Calcineurin." Biochem. J. Vol. 270 No. 43: 25651-25655 (1995).
	C4	Durfee et al. "The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit." Genes & Develop. 7: 555-569 (1993).
	C5	Edwards et al., "Peptidyl α -Ketoheterocyclic Inhibitors of Human Neutrophil Elastase. 2. Effect of Varying the Heterocyclic Ring on <i>in Vitro</i> Potency." J. Med. Chem 38: 76-85 (1995).
	C6	Griffin et al., "Specific Covalent Labeling of Recombinant Protein Molecules Inside Live Cells." Science 281: 269-272 (1998).
	C7	Hanzlik et al., "Reversible covalent binding of peptide nitriles to papain." Biochimica et Biophysica Acta 1035: 62-70 (1990).
	C8	Li et al., "7-Substituted, 1,4,6-androstatriene-3, 17-diones as enzyme-activated irreversible inhibitors of aromatase." L. steroid Biochem. 36: 533-539 (1990).
	C9	Licitra and Liu, "A three-hybrid system for detecting small ligand-protein receptor interactions." Proc. Natl. Acad. Sci. 93: 12817-12821 (1996).
	C10	Mendelsohn and Brent, "Applications of interaction traps/two-hybrid systems to biotechnology research." Current



OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
PP		Opinion in Biochemistry 5: 482-486 (1994).
PP	C11.	Michels et al., "Combinatorial diocatalysis: a natural approach to drug discovery." TIBTECH 16: 210-215 (1998).
	C12.	Mueller et al., "Leukotriene A ₄ hydrolase: Mapping of a henicosapeptide involved in mechanism-based inactivation." Proc. Natl. Acad. Sci. 92: 8383-8387 (1995).
	C13	O'Brien et al., "Inhibition of monoamine oxidase by clorgyline analogues." J. Neural Transm. [Supple]41: 295-305 (1994).
	C14	Pruschy et al., "Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012." Chemistry and Biology 1: 163-172 (1994).
	C15	Roth and Siok, "Acetylation of the NH ₂ -terminal Serine of Prostaglandin Synthetase by Aspirin." The Journal of Biological Chemistry Vol 253 No. 11: 3782-3784 (1978).
	C16	Salto et al., "In Vitro Characterization of Nonpeptide Irreversible Inhibitors of HIV Protease." The Journal of Biological Chemistry Vol. 269 No. 14: 10691-10698 (1994).
	C17	Schenkein and Pratt, "Phenylpropynal, a specific, irreversible, non-β-lactam inhibitor of β-Lactamases." The Journal of Biological Chemistry Vol. 255, No. 1: 45-48 (1980).
	C18	Silverman, "[10] Mechanism-Based Enzyme Inactivators." Methods in Enzymology 249: 240-283 (1995).
	C19	Singh et al., "Structure-based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases." J. Med. Chem. 40: 1130-1135 (1997).
	C20	Snider and Brueggermeier, "Covalent modification of aromatase by a radiolabeled irreversible inhibitor." L. steroid Biochem. Vol. 22 No. 3: 325-330 (1985).
	C21	Tous et al., "O'-(Epoxyalkyl) tyrosines and (Epoxyalkyl) Phenylalanine as Irreversible Inactivators of Serine Proteases: Synthesis and Inhibition Mechanism." J. Med. Chem 33: 1620-1634 (1990).
	C22	Yang et al., "Protein-peptide interactions analyzed with the yeast two-hybrid system." Nucleic Acids Research Vol. 23 No. 7: 1152-1156 (1995).
	C23	Zaugg et al., "Modification of Hemoglobin with Analogs of Aspirin." The Journal of Biological Chemistry Vol. 255 No. 7: 2816-2821 (1980).
✓	C24	Zhang et al., "Rationally Designed Inhibitors of Inosine Monophosphate Dehydrogenase." J. Med. Chem. 40: 4-8 (1997).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	<i>P. Ponnalan</i>	Date Considered	<i>10/18/00</i>
--------------------	--------------------	-----------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRADOCS:1270786.2(r8jm02!.DOC)